1. Bauml MA, Underwood DA. Left ventricular hypertrophy: an overlooked cardiovascular risk factor. Cleveland Clin J Med. 2010;77(6):381-387.
  2. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis. 2009;52(2):153-167.
  3. Lovic D, Erdine S, Catakoğlu AB. How to estimate left ventricular hypertrophy in hypertensive patients. Anadolu Kardiyol Derg. 2014;14(4):389-395.
  4. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589.
  5. Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. J Am Soc Hypertens. 2011;5(6):449-455.
  6. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52(4):857-864.
  7. Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant hypertension and left ventricular hypertrophy: an overview. J Am Soc Hypertens. 2010;4(6):319-324.
  8. Cuspidi C, Rescaldani M, Sala C, Negri F, Grassi G, Mancia G. Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension: an updated review. J Hypertens. 2012A;30(11):2066-2073.
  9. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A, Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an update review of echocardiographic studies. J Hum Hypertens. 2012B;26:343-349.
  10. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs. 1988;35(suppl 5):1-5.
  11. Hanratty C, McAuley D, Silke B. Epidemiology and treatment of left ventricular hypertrophy in the elderly. Coron Artery Dis. 1999;10(8):633-640.
  12. Cuspidi C, Sala C, Zanchetti A. Management of hypertension in patients with left ventricular hypertrophy. Curr Hypertens Rep. 2007;9(6):498-505.
  13. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-1357.
  14. Milan A, Caserta MA, Avenatti E, Abram S, Veglio F. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. Intern Emerg Med. 2010;5(6):469-479.
  15. Mancia G, DeBacker G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
  16. Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19:303–309.
  17. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001 Sep 11;104(11):1248-54.
  18. Cheung BM, Lau CP. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Br J Clin Pharmacol. 1999 Feb;47(2):179-87.
  19. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002;20:2293–2300.
  20. Dalhof B, Sever S, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005a;366:895–906.
  21. Agabiti-Rosei E, Trimarco B, Muiesan ML, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2005, 23:1091–1098.
  22. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation 2004, 110:1456–1462.
  23. Dahlof B, Zanchetti A, Diez J, et al; REGAAL Study Investigators.Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002 Sep;20(9):1855-64.
  24. Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005b;23:2063–2070.
  25. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831–1838.
  26. Mathew J et al (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615–1621.